119 related articles for article (PubMed ID: 37516153)
1. T4 bacteriophage nanoparticles engineered through CRISPR provide a versatile platform for rapid development of flu mucosal vaccines.
Li M; Chen C; Wang X; Guo P; Feng H; Zhang X; Zhang W; Gu C; Zhu J; Wen G; Feng Y; Xiao L; Peng G; Rao VB; Tao P
Antiviral Res; 2023 Sep; 217():105688. PubMed ID: 37516153
[TBL] [Abstract][Full Text] [Related]
2. Bacteriophage T4 Vaccine Platform for Next-Generation Influenza Vaccine Development.
Li M; Guo P; Chen C; Feng H; Zhang W; Gu C; Wen G; Rao VB; Tao P
Front Immunol; 2021; 12():745625. PubMed ID: 34712234
[TBL] [Abstract][Full Text] [Related]
3. Homologous Sequential Immunization Using Salmonella Oral Administration Followed by an Intranasal Boost with Ferritin-Based Nanoparticles Enhanced the Humoral Immune Response against H1N1 Influenza Virus.
Wang Z; Zhang T; Jia F; Ge C; He Y; Tian Y; Wang W; Yang G; Huang H; Wang J; Shi C; Yang W; Cao X; Zeng Y; Wang N; Qian A; Wang C; Jiang Y
Microbiol Spectr; 2023 Jun; 11(3):e0010223. PubMed ID: 37154735
[TBL] [Abstract][Full Text] [Related]
4. A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague.
Tao P; Mahalingam M; Zhu J; Moayeri M; Sha J; Lawrence WS; Leppla SH; Chopra AK; Rao VB
mBio; 2018 Oct; 9(5):. PubMed ID: 30327445
[No Abstract] [Full Text] [Related]
5. Porous Nanoparticles With Self-Adjuvanting M2e-Fusion Protein and Recombinant Hemagglutinin Provide Strong and Broadly Protective Immunity Against Influenza Virus Infections.
Bernasconi V; Bernocchi B; Ye L; Lê MQ; Omokanye A; Carpentier R; Schön K; Saelens X; Staeheli P; Betbeder D; Lycke N
Front Immunol; 2018; 9():2060. PubMed ID: 30271406
[TBL] [Abstract][Full Text] [Related]
6. Recombinant baculovirus vaccine containing multiple M2e and adjuvant LTB induces T cell dependent, cross-clade protection against H5N1 influenza virus in mice.
Zhang J; Fan HY; Zhang Z; Zhang J; Zhang J; Huang JN; Ye Y; Liao M
Vaccine; 2016 Jan; 34(5):622-629. PubMed ID: 26724200
[TBL] [Abstract][Full Text] [Related]
7. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine.
Carignan D; Thérien A; Rioux G; Paquet G; Gagné ML; Bolduc M; Savard P; Leclerc D
Vaccine; 2015 Dec; 33(51):7245-7253. PubMed ID: 26549362
[TBL] [Abstract][Full Text] [Related]
8. Intranasal Nanovaccine Confers Homo- and Hetero-Subtypic Influenza Protection.
Qi M; Zhang XE; Sun X; Zhang X; Yao Y; Liu S; Chen Z; Li W; Zhang Z; Chen J; Cui Z
Small; 2018 Mar; 14(13):e1703207. PubMed ID: 29430819
[TBL] [Abstract][Full Text] [Related]
9. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
[TBL] [Abstract][Full Text] [Related]
10. Mucosal vaccination of conserved sM2, HA2 and cholera toxin subunit A1 (CTA1) fusion protein with poly gamma-glutamate/chitosan nanoparticles (PC NPs) induces protection against divergent influenza subtypes.
Chowdhury MYE; Kim TH; Uddin MB; Kim JH; Hewawaduge CY; Ferdowshi Z; Sung MH; Kim CJ; Lee JS
Vet Microbiol; 2017 Mar; 201():240-251. PubMed ID: 28284616
[TBL] [Abstract][Full Text] [Related]
11. CRISPR Engineering of Bacteriophage T4 to Design Vaccines Against SARS-CoV-2 and Emerging Pathogens.
Zhu J; Ananthaswamy N; Jain S; Batra H; Tang WC; Rao VB
Methods Mol Biol; 2022; 2410():209-228. PubMed ID: 34914049
[TBL] [Abstract][Full Text] [Related]
12. Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice.
Kim EH; Park HJ; Han GY; Song MK; Pereboev A; Hong JS; Chang J; Byun YH; Seong BL; Nguyen HH
J Virol; 2014 Sep; 88(17):9693-703. PubMed ID: 24920793
[TBL] [Abstract][Full Text] [Related]
13. Potential recombinant vaccine against influenza A virus based on M2e displayed on nodaviral capsid nanoparticles.
Yong CY; Yeap SK; Ho KL; Omar AR; Tan WS
Int J Nanomedicine; 2015; 10():2751-63. PubMed ID: 25897220
[TBL] [Abstract][Full Text] [Related]
14. Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats.
Wang W; Huang B; Wang X; Tan W; Ruan L
Virol Sin; 2019 Oct; 34(5):583-591. PubMed ID: 31240620
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticles based on artificial self-assembling peptide and displaying M2e peptide and stalk HA epitopes of influenza A virus induce potent humoral and T-cell responses and protect against the viral infection.
Zykova AA; Blokhina EA; Stepanova LA; Shuklina MA; Tsybalova LM; Kuprianov VV; Ravin NV
Nanomedicine; 2022 Jan; 39():102463. PubMed ID: 34583058
[TBL] [Abstract][Full Text] [Related]
16. A versatile papaya mosaic virus (PapMV) vaccine platform based on sortase-mediated antigen coupling.
Thérien A; Bédard M; Carignan D; Rioux G; Gauthier-Landry L; Laliberté-Gagné MÈ; Bolduc M; Savard P; Leclerc D
J Nanobiotechnology; 2017 Jul; 15(1):54. PubMed ID: 28720097
[TBL] [Abstract][Full Text] [Related]
17. Recombinant M2e outer membrane vesicle vaccines protect against lethal influenza A challenge in BALB/c mice.
Rappazzo CG; Watkins HC; Guarino CM; Chau A; Lopez JL; DeLisa MP; Leifer CA; Whittaker GR; Putnam D
Vaccine; 2016 Mar; 34(10):1252-8. PubMed ID: 26827663
[TBL] [Abstract][Full Text] [Related]
18. Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge.
Hashemi H; Pouyanfard S; Bandehpour M; Noroozbabaei Z; Kazemi B; Saelens X; Mokhtari-Azad T
PLoS One; 2012; 7(9):e45765. PubMed ID: 23029232
[TBL] [Abstract][Full Text] [Related]
19. Nanoclusters self-assembled from conformation-stabilized influenza M2e as broadly cross-protective influenza vaccines.
Wang L; Hess A; Chang TZ; Wang YC; Champion JA; Compans RW; Wang BZ
Nanomedicine; 2014 Feb; 10(2):473-82. PubMed ID: 23988715
[TBL] [Abstract][Full Text] [Related]
20. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
